tirzepatide surpass-5 Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6) Tirzepatide outcompetes long-acting insulin in

Its not about willpower, it's about science backed results Wegovy is FDA-approved for weight loss and may improve cardiovascular health

It is also important to be aware of the possible side effects and to contact your doctor if you have any concerns

A combined approachGLP-1 therapy plus lifestyle modifications plus appropriate medicationtypically yields the best lipid outcomes

This is Epithalons signature mechanism and the one most cited in longevity literature

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that showed up to 24.2% weight loss in phase 2 trials at 48 weeks, potentially exceeding both CagriSema and tirzepatide